Treg-targeted IL-2/anti-IL-2 complex controls graft-versus-host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation

The work of Allan Thiolat and Caroline Pilon, members of José Cohen’s Immunoregulation and Biotherapy (I-BIOT) team, recently published in the September 14, 2023 issue of Haematologica (, has just been reprinted in the September 15, 2023 issue of Stem cells Science News in the Immune Regulation News section (

This is the first study to compare side-by-side the respective effects of two complexes [IL-2/Ac anti-IL-2] designed to activate either regulatory or effector T cells. This work demonstrates the advantage of the pro-regulatory T complex both in terms of graft-versus-host disease control and the anti-leukemic effect produced.